Alpha 2.0
Login Register
» Articles » PMID: 3409441

Flavone Acetic Acid: a Nonlinear Pharmacokinetic Model

Overview
Journal Cancer Chemother Pharmacol
Specialty Oncology
Date 1988 Jan 1
PMID 3409441
Citations 9
Authors
A Gouyette
D J Kerr
S B Kaye
A Setanoians
J Cassidy
C Bradley
G Forrest
M Soukop
Affiliations
Soon will be listed here.
Abstract

Flavone acetic acid pharmacokinetics were studied in 31 patients in a phase I clinical trial. The drug was given by i.v. infusions over 1, 1.5, 3, and 6 h at doses ranging from 0.5 to 6.4 g/m2. The pharmacokinetic parameters were determined according to a nonlinear model including Michaelis-Menten-type kinetics. The mean elimination half-life is 4.8 h and the mean volume of distribution of the central compartment, 7.61. Our model predicted a maximal tolerated dose (MTD) of 11.1 g/m2 on the basis of the "therapeutic window" concept, very close to the clinically observed MTD of 10 g/m2. This model is also operational when different protocols of inoculation are considered, such as a divided-dose schedule vs a unique infusion, and indicates that, at the MTD, injections should be made every 72 h to avoid drug accumulation.

Citing Articles

Mathematical analysis and drug exposure evaluation of pharmacokinetic models with endogenous production and simultaneous first-order and Michaelis-Menten elimination: the case of single dose.

Wu X, Nekka F, Li J J Pharmacokinet Pharmacodyn. 2018; 45(5):693-705.

PMID: 29987574 DOI: 10.1007/s10928-018-9599-4.

Saturable elimination and saturable protein binding account for flavone acetic acid pharmacokinetics.

Relling M, Evans R, Groom S, Crom W, Pratt C J Pharmacokinet Biopharm. 1993; 21(6):639-51.

PMID: 8138891 DOI: 10.1007/BF01113499.

Phase I and pharmacology study of flavone acetic acid administered two or three times weekly without alkalinization.

De Forni M, Chabot G, Armand J, Gouyette A, Recondo G Cancer Chemother Pharmacol. 1995; 35(3):219-24.

PMID: 7805180 DOI: 10.1007/BF00686551.

Flavone acetic acid (LM-975; NSC-347512) activation to cytotoxic species in vivo and in vitro.

Chabot G, Bissery M, Gouyette A Cancer Chemother Pharmacol. 1989; 24(5):273-6.

PMID: 2758556 DOI: 10.1007/BF00304757.

Flavone acetic acid distribution in human malignant tumors.

Damia G, Freschi A, Sorio R, Braida A, Caruso G, Quaia M Cancer Chemother Pharmacol. 1990; 26(1):67-70.

PMID: 2322990 DOI: 10.1007/BF02940298.

References
1.
Kerr D, Kaye S, Graham J, Cassidy J, Harding M, Setanoians A . Phase I and pharmacokinetic study of LM985 (flavone acetic acid ester). Cancer Res. 1986; 46(6):3142-6. View
2.
Mcainsh J, Gay M . Theoretical Michaelis-Menten elimination model for propranolol. Eur J Drug Metab Pharmacokinet. 1985; 10(3):241-5. DOI: 10.1007/BF03189748. View
3.
DArgenio D, Schumitzky A . A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed. 1979; 9(2):115-34. DOI: 10.1016/0010-468x(79)90025-4. View
4.
Gouyette A, Ducret J, CAILLE P, AMIEL J, Rouesse J, Foka M . Preliminary phase I clinical study and pharmacokinetics of (1,2-diaminocyclohexane) (isocitrato) platinum (II) or PHIC. Anticancer Res. 1986; 6(5):1127-32. View
5.
Gouyette A, Huertas D, Droz J, Rouesse J, AMIEL J . Pharmacokinetics of 2-methyl-9-hydroxyellipticinium acetate (NSC-264137) in cancer patients (phase I study). Eur J Cancer Clin Oncol. 1982; 18(12):1285-92. DOI: 10.1016/0277-5379(82)90130-4. View